Our study identifies SCD1-mediated lipid remodeling as a key driver of enhanced membrane fluidity and metastatic potential in CM. Inhibition of SCD1 increases lipid saturation, reduces membrane fluidity, induces oxidative stress, and suppresses liver and lung metastasis. The MAFG-METTL14-SCD1 axis thus represents a critical regulator of CM progression, and combined therapeutic targeting with aramchol and S-HFD offers promising translational potential.

2 months ago

Journal

METTL14 (Methyltransferase 14)

Aramchol (aramchol meglumine)

2ms

Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet (clinicaltrials.gov)

P1, N=32, Not yet recruiting, Galmed Pharmaceuticals Ltd

2 months ago

New P1 trial

Aramchol (aramchol meglumine)

2ms

The Precision CAD Trial (clinicaltrials.gov)

P=N/A, N=276, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting | N=450 --> 276

2 months ago

Enrollment closed • Enrollment change

2ms

Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets (clinicaltrials.gov)

P1, N=16, Active, not recruiting, Galmed Pharmaceuticals Ltd | Trial completion date: May 2025 --> Dec 2025

2 months ago

Trial completion date

Aramchol (aramchol meglumine)

3ms

Targeting drug-resistant cancers: in silico repurposing of the cholesterol-lowering drug Ezetimibe for selective inhibition of aldo-keto reductase 1B10 (AKR1B10). (PubMed, SAR QSAR Environ Res)

Quantum mechanical analysis indicated favourable electronic properties and chemical stability. These results suggest that Ezetimibe is a selective and stable AKR1B10 inhibitor, warranting further investigation for drug-resistant cancer therapy.

3 months ago

Journal

AKR1B10 (Aldo-Keto Reductase Family 1 Member B10)

3ms

Targeting Stearoyl-CoA Desaturase‑1 (SCD1) by the Drug-Nutraceutical Combination of Montelukast and Bixin in Ameliorating Steatotic NAFLD. (PubMed, ACS Omega)

The combination treatment showed a significant reduction of 21.64% (P < 0.05) in lipid accumulation relative to individual treatment with Bixin or Montelukast and was comparable with the reference drug Aramchol (21.83%). The markers of oxidative stress were also significantly reduced (P < 0.05), evidenced by decreased MDA (42.25%), RNS levels (32.59%), and ROS levels (30.72%) in the combination group. These findings suggest that Bixin and Montelukast in combination hold potential for managing the multiple aspects in the pathophysiology of NAFLD development and progression.

3 months ago

Journal

SCD (Stearoyl-CoA Desaturase)

Aramchol (aramchol meglumine)

4ms

Musashi: A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia (clinicaltrials.gov)

P=N/A, N=2560, Not yet recruiting, Daiichi Sankyo

4 months ago

New trial

4ms

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib (clinicaltrials.gov)

P=N/A, N=8606, Recruiting, Boryung Pharmaceutical Co., Ltd | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026

4 months ago

Trial completion date • Trial primary completion date • Real-world evidence

pitavastatin

5ms

Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment (clinicaltrials.gov)

P=N/A, N=18000, Active, not recruiting, Daewoong Pharmaceutical Co. LTD. | Trial completion date: Jun 2025 --> Dec 2025

5 months ago

Trial completion date • Real-world evidence

6ms

GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification (clinicaltrials.gov)

P4, N=7435, Recruiting, Asan Medical Center | Not yet recruiting --> Recruiting

6 months ago

Enrollment open

pitavastatin